Join
Live feed
·
PRReleasevia Quantisnow
Replimune Group Inc. logo

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

ByQuantisnow·Wall Street's wire, on your screen.
REPL· Replimune Group Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track REPL (Replimune Group Inc.) and more on Quantisnow.